HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Olivia Stancil

Olivia Stancil

Senior Clinical Trial Assistant

Olivia Stancil joins Genprex as a Senior Clinical Trial Assistant where she supports the clinical operations team with the preparation, handling, distribution, filing, and archiving of clinical trial documentation. Mrs. Stancil acts as both a Functional Trial Master File (TMF) Specialist and a Clinical Trial Management System (CTMS) Specialist.

Mrs. Stancil brings a wide breadth of experience ranging from multiple industries across multiple roles to the Genprex team. Prior to joining Genprex, she started her career in pharmaceutical sales with Johnson & Johnson and went on to carry a management leadership role for ten years in a non-profit that provided cancer support services and resources to oncology patients and their families. Most recently, she spent two years at PSI CRO providing support for oncology and diabetes clinical trials.  Mrs. Stancil graduated from Michigan State University with a Bachelor of Science from the College of Agriculture and Natural Resources.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes May 7
  • Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma May 6
  • Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting Apr 29
Designed and Secured by Barsec
Copyright ©2025 all rights reserved.
Home - Privacy Policy - Terms of Use